Results 101 to 110 of about 9,113,589 (351)

Nutrition and Crohn's Disease: An Overview

open access: yesCanadian Journal of Gastroenterology, 1990
Malnutrition is common in Crohn's disease. Nutrition can be improved in patients with Crohn's disease by total parenteral nutrition (TPN) or enteral nutrition. TPN induces long term remission in over 50% of patients with Crohn's disease.
C Ó'Moráin
doaj   +1 more source

Multidrug resistance 1 gene polymorphisms may determine Crohn's disease behavior in patients from Rio de Janeiro

open access: yesClinics, 2014
OBJECTIVES: Conflicting data from studies on the potential role of multidrug resistance 1 gene polymorphisms in inflammatory bowel disease may result from the analysis of genetically and geographically distinct populations.
Ana Teresa P. Carvalho   +11 more
doaj   +1 more source

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt   +7 more
wiley   +1 more source

Severe airway stenosis associated with Crohn's disease: Case report

open access: yesBMC Pulmonary Medicine, 2006
Background Symptomatic respiratory tract involvement is not common in Crohn's disease. Upper-airway obstruction has been reported before in Crohn's disease and usually responds well to steroid treatment.
Ernst Armin   +5 more
doaj   +1 more source

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

open access: yesNew England Journal of Medicine, 2012
BACKGROUND In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown.
W. Sandborn   +16 more
semanticscholar   +1 more source

The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Shunting (hypermethylating) thiopurine metabolism, characterized by excessive 6‐MMPR production and (sub)therapeutic 6‐TGN levels, poses a significant challenge in the treatment of inflammatory bowel disease (IBD). This study evaluates the metabolic outcomes of switching to low‐dose thiopurine with allopurinol (LDTA) or thioguanine (TG) in IBD ...
Ahmed B. Bayoumy   +4 more
wiley   +1 more source

Ulcerative colitis and Crohn's disease: is Mycobacterium avium subspecies paratuberculosis the common villain?

open access: yesGut Pathogens, 2010
Mycobacterium avium, subspecies paratuberculosis (MAP) causes a chronic disease of the intestines in dairy cows and a wide range of other animals, including nonhuman primates, called Johne's ("Yo-knee's") disease.
Pierce Ellen S
doaj   +1 more source

The prevalence of polypharmacy increases with age among patients with inflammatory bowel disease: A nationwide cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Polypharmacy is common in adult patients with inflammatory bowel disease (IBD). This study aims to quantify medication prescriptions and estimate the risk of polypharmacy over time in older adults with IBD. Methods In a nationwide cohort of adult incident IBD patients from 1 April 1996, to 31 December 2019, we examined medication prescriptions ...
Ken Lund   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy